Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers

NCT07370155 | Not Yet Recruiting Phase 1

• 1 other identifier: D-4517-003
• Study Type: interventional
• Target: 36
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

• Safety and Tolerability of MGB

  Safety will be assessed throughout the study by monitoring adverse events (AEs), including their incidence, severity, and relationship to study treatment. Additional safety assessments will include clinical laboratory evaluations (hematology, clinical chemistry, and urinalysis), physical examinations, and vital sign measurements, including pulse rate, blood pressure (BP), respiration rate, and tympanic temperature.

  Varying timepoints through end of treatment, up to approximately 22 days.

Secondary Outcomes (5)

• Pharmacokinetic Parameter Area Under the Curve (AUC) for MGB

  Varying timepoints through end of treatment, up to approximately 22 days.

• Pharmacokinetic Parameter Maximum Concentration (Cmax) for MGB

  Varying timepoints through end of treatment, up to approximately 22 days.

• Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for MGB

  Varying timepoints through end of treatment, up to approximately 22 days.

• Pharmacokinetic Parameter Total Clearance (CL) for MGB

  Varying timepoints through end of treatment, up to approximately 22 days.

• Pharmacokinetic Parameter Apparent Terminal Half-life (t1/2) for MGB

  Varying timepoints through end of treatment, up to approximately 22 days.

Study Arms (3)

MGB 200 mg

EXPERIMENTAL

Participants receive MGB 200 mg administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

Drug: MGB 200 mg

MGB 400 mg

EXPERIMENTAL

Participants receive MGB 400 mg administered subcutaneously once weekly on Days 1, 8, and 15 following Safety Review Committee approval.

Drug: MGB 400 mg

MGB 600 mg

EXPERIMENTAL

Participants receive MGB 600 mg administered subcutaneously once weekly on Days 1, 8, and 15, contingent upon acceptable safety and tolerability in prior cohorts.

Drug: MGB 600 mg

Interventions

MGB 600 mg DRUG

Participants receive the highest planned dose of MGB administered subcutaneously

MGB 600 mg

MGB 200 mg DRUG

Participants receive weekly subcutaneous administration of MGB

MGB 200 mg

MGB 400 mg DRUG

Participants receive an intermediate dose of MGB administered subcutaneously once weekly

MGB 400 mg

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit
• Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to any study-related procedures being completed
• Is in general good health, based upon the results of a medical history assessment, physical examination, vital signs, and laboratory profile, as judged by the Investigator
• Female participants of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 1 year, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the central laboratory's ranges
• All female participants of childbearing potential with male partners and male participants with female partners of childbearing potential must consent to use 2 (two) highly effective methods of contraception from start of study and for at least 90 days following the EOS visit or last dose of study treatment, whichever is later. Women of childbearing potential on hormonal contraceptives must be stable on the medication for at least 2 menstrual cycles prior to Day -1.
• The following are acceptable methods of highly effective contraception:
• Using twice the normal protection of birth control by using a condom AND one other form of contraception; either birth control pills (The Pill), or injectable birth control, birth control patch or contraceptive implant associated with inhibition of ovulation, or intrauterine device; or
• Surgical sterilization as a single form of birth control: i.e., tubal ligation, hysterectomy, bilateral oophorectomy, vasectomy, or equivalently effective surgical form of birth control (with documented proof of the absence of sperm in the post-vasectomy ejaculate) at least 6 months prior to screening; or
• True sexual abstinence for the duration of the study and for at least 12 weeks following the EOS visit or after the last dose of IP, whichever is later, is acceptable only when in line with the preferred and usual lifestyle of the participant.
• Periodic abstinence (calendar, symptothermal, post ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.
• If male, participants must agree to abstain from sperm donation through 90 days after administration of the last dose of study drug
• If female, participants must refrain from donation of ova from start of study and for 120 days after last dose of investigational drug
• Female participants may not be pregnant, lactating, or breastfeeding
• Female participants of childbearing potential must have a negative pregnancy test at screening and Check-in (Day -1)
• Participants must have a negative test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVab), and human immunodeficiency virus (HIV) antibody at screening

You may not qualify if:

• Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal (GI), hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies), or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the participant at an unacceptable risk as a participant in this study
• Evidence of systemic inflammation as measured by C-reactive protein above the upper limit of normal, as measured by the local lab
• History of malignancy (other than successfully treated basal cell or squamous cell skin cancer)
• History or presence of an abnormal electrocardiogram (ECG) that, in the opinion of the Investigator, is clinically significant
• Has had an acute illness considered clinically significant by the Investigator within 30 days prior to screening
• History of alcoholism or drug abuse within 1 year prior to screening or excessive alcohol consumption defined as \>14 standard drinks per week.
• Has used any product containing nicotine within 30 days prior to screening or intends to use any product containing nicotine during the study (exception of ≤ 5 cigarettes per week)
• Has had any immunizations (live vaccines) in the 4 weeks prior to screening; COVID-19 vaccination within 7 days of Day 1
• Has used any prescription (with the exception of hormonal contraceptives) or over-the counter medication (with the exception of acetaminophen), vitamins/herbal supplements within7 days prior to Day 1
• Has used any other study drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to Day 112. Has lost or donated \> 450 mL of whole blood or blood products within 7 days prior to screening
• \. Investigator has reason to believe that the participant may be unable to fulfill the protocol visit schedule or requirements 14. Has any finding that, in the view of the Investigator or Medical Monitor, would compromise the participant's safety requirements 15. Is employed by the Sponsor, the Contract Research Organization (CRO), or the study site (permanent, temporary contract worker, or designee responsible for the conduct of the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor, CRO, or study site employee

Sponsors & Collaborators

• Ashvattha Therapeutics, Inc.: lead

MeSH Terms

Interventions

Myoglobin

Intervention Hierarchy (Ancestors)

Muscle Proteins; Contractile Proteins; Proteins; Amino Acids, Peptides, and Proteins; Globins; Hemeproteins

Central Study Contacts

Susan Schneider

CONTACT

9176472867; sschneider@avttx.com

Jeff Cleland

CONTACT

(650) 868-5853; jeff@avttx.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 19, 2026
• First Posted: January 27, 2026
• Study Start: January 29, 2026
• Primary Completion (Estimated): May 13, 2026
• Study Completion (Estimated): June 10, 2026
• Last Updated: February 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share